GOVERNMENT COUNSEL, LLC for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
President's Budget For A Better America (FY2020) relating to generic exclusivity
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Health Issues HCR
H.R. 1506-Fair And Immediate Release of Generic Drugs Act; H.R.1499-Protecting Consumer Access to Generic Drugs Act of 2019; H.R. 938-The Blocking Act of 2019.Implementation of Public Law 115-52, the FDA Reauthorization Act of 2017, Section 808, Incentivizing Generic Drug Developments, provisions relating to exclusivity for competitive generic therapies.
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.